GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LENSAR Inc (NAS:LNSR) » Definitions » Cash Ratio

LENSAR (LENSAR) Cash Ratio : 2.07 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is LENSAR Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. LENSAR's Cash Ratio for the quarter that ended in Dec. 2023 was 2.07.

LENSAR has a Cash Ratio of 2.07. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for LENSAR's Cash Ratio or its related term are showing as below:

LNSR' s Cash Ratio Range Over the Past 10 Years
Min: 0.59   Med: 2.07   Max: 4.79
Current: 2.07

During the past 5 years, LENSAR's highest Cash Ratio was 4.79. The lowest was 0.59. And the median was 2.07.

LNSR's Cash Ratio is ranked better than
63.51% of 855 companies
in the Medical Devices & Instruments industry
Industry Median: 1.23 vs LNSR: 2.07

LENSAR Cash Ratio Historical Data

The historical data trend for LENSAR's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENSAR Cash Ratio Chart

LENSAR Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
0.59 4.79 3.63 1.28 2.07

LENSAR Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 0.80 2.41 2.26 2.07

Competitive Comparison of LENSAR's Cash Ratio

For the Medical Devices subindustry, LENSAR's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LENSAR's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LENSAR's Cash Ratio distribution charts can be found below:

* The bar in red indicates where LENSAR's Cash Ratio falls into.



LENSAR Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

LENSAR's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=24.064/11.632
=2.07

LENSAR's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=24.064/11.632
=2.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LENSAR  (NAS:LNSR) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


LENSAR Cash Ratio Related Terms

Thank you for viewing the detailed overview of LENSAR's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


LENSAR (LENSAR) Business Description

Traded in Other Exchanges
N/A
Address
2800 Discovery Drive, Orlando, FL, USA, 32826
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Nr-gri Partners Gp, Llc 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Nr-gri Partners, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Todd B Hammer director, 10 percent owner NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116
Thomas B Ellis director, 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
North Run Advisors, Llc 10 percent owner 62 WALNUT STREET, WELLESLEY MA 02481
North Run Capital, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Staab Thomas R Ii officer: Chief Financial Officer C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Kendra Wong officer: Principal Accounting Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Alan B. Connaughton officer: Chief Operating Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Nicholas T Curtis director, officer: Chief Executive Officer C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016
Pdl Biopharma, Inc. 10 percent owner 59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391